Research Article

Proteomic Study of HPV-Positive Head and Neck Cancers: Preliminary Results

Géraldine Descamps,¹ Ruddy Wattiez,² and Sven Saussez¹

¹ *Laboratory of Anatomy and Cell Biology, Faculty of Medicine and Pharmacy, University of Mons, Pentagone 2A, Avenue du Champ de Mars 6, 7000 Mons, Belgium*

² *Laboratory of Proteomics and Microbiology, Faculty of Sciences, University of Mons, Mons, Belgium*

Correspondence should be addressed to Sven Saussez; sven.saussez@hotmail.com

Received 15 November 2013; Revised 20 January 2014; Accepted 23 January 2014; Published 2 March 2014

Academic Editor: Vincent Grégoire

Copyright © 2014 Géraldine Descamps et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Human papillomavirus (HPV) was recently recognized as a new risk factor for head and neck squamous cell carcinoma. For oropharyngeal cancers, an HPV+ status is associated with better prognosis in a subgroup of nonsmokers and nondrinkers. However, HPV infection is also involved in the biology of head and neck carcinoma (HNC) in patients with a history of tobacco use and/or alcohol consumption. Thus, the involvement of HPV infection in HN carcinogenesis remains unclear, and further studies are needed to identify and analyze HPV-specific pathways that are involved in this process. Using a quantitative proteomics-based approach, we compared the protein expression profiles of two HPV+ HNC cell lines and one HPV– HNC cell line. We identified 155 proteins that are differentially expressed ($P < 0.01$) in these three lines. Among the identified proteins, prostate stem cell antigen (PSCA) was upregulated and eukaryotic elongation factor 1 alpha (EEF1 α) was downregulated in the HPV+ cell lines. Immunofluorescence and western blotting analyses confirmed these results. Moreover, PSCA and EEF1 α were differentially expressed in two clinical series of 50 HPV+ and 50 HPV– oral cavity carcinomas. Thus, our study reveals for the first time that PSCA and EEF1 α are associated with the HPV-status, suggesting that these proteins could be involved in HPV-associated carcinogenesis.

1. Introduction

Head and neck cancers (HNCs) constitute a heterogeneous group of tumors that often arise in the oral cavity, oropharynx, hypopharynx, and larynx. HNC is the sixth most common cancer, with as many as 466,831 new cases diagnosed in men in 2008 [1]. HNC generally has a poor prognosis; its 5-year survival rate ranges between 40 and 50%. HNC patients usually have histories of heavy tobacco and alcohol consumption. However, the International Agency for Research in Cancer (IARC) has recently recognized human papillomavirus (HPV) as a risk factor for oropharyngeal squamous cell carcinoma (OSCC). Indeed, numerous studies have provided consistent evidence that HPV has an etiologic role in 20 to 50% of OSCCs, and it is associated with a better prognosis in terms of survival and response to therapy [2].

Although the relationship between HPV infection and patient prognosis seems clear in oropharyngeal carcinoma,

this relationship is less evident in the other anatomical sites affected by HNC, such as the oral cavity, larynx, and hypopharynx. The meta-analysis performed by Ragin and Taioli, which examined the relationship between HPV and overall survival, did not show any differences between HPV+ and HPV– patients with cancers at nonoropharyngeal sites [3]. Recently, we demonstrated that HPV+ oral SCC patients with a history of tobacco use and/or alcohol consumption have a significantly poorer prognosis compared to HPV– patients [4], and two Swedish studies reported that oral HPV infection is associated with a dramatically increased risk of recurrence in oral SCCs [5, 6]. However, other studies have failed to demonstrate an association between HPV status and prognosis [7–9]. Therefore, it seems clear that the biology of oropharyngeal tumors in younger patients, nondrinkers, and non-smokers is distinct from that of nonoropharyngeal SCC in older patients and those with a history of tobacco use and/or alcohol consumption [10]. While it is unclear whether

TABLE 1: Description of the characteristics of the cell lines used.

Cell line name	Anatomical site	TNM stage	Sex	HPV status	Origin
FaDU	Hypopharynx	TxNxMx	Male	HPV-negative	ATCC
UPCI-SCC-131	Oral cavity	T2N2M0	Male	HPV-negative	ATCC
Detroit 562	Pharynx	TxNxMx	Female	HPV-negative	ATCC
UPCI-SCC-90	Oropharynx	T2N1M0	Male	HPV-positive	ATCC
93VU-147T	Oral cavity	T4N2	Male	HPV-positive	University Medical Center of Amsterdam
UPCI-SCC-154	Oral cavity	T4N2	Male	HPV-positive	ATCC

tobacco is a risk factor for HPV-induced oropharyngeal tumors, smoking has a negative impact on the survival of HPV+ patients [11]. Thus, researchers agree that there are several possible physiological states according to the patient's HPV infection status, which may or may not be associated with the classical risk factors. Therefore, it is important to understand these differences and the signaling pathways responsible for HPV infection.

Proteomic analysis represents a promising approach for identifying HPV-related signaling pathways. However, a paucity of literature exists regarding the biology of HPV-mediated head and neck tumors. A small number of proteomic studies have been conducted, and these investigations have identified HPV-specific protein candidates in HNC. Additional proteins with altered expression levels were previously identified using 2D electrophoresis followed by mass spectrometry. S100A8, a calcium-binding protein, is a powerful biomarker of HPV18 infection in oral SCC patients [12] and is involved in tumor development and progression [13]. In another study, Melle et al. detected two interesting protein markers that were significantly upregulated in HPV+ oral SCC, TRX and E-FABP [14].

Here, we used a quantitative proteomic-based approach to visualize major changes in protein expression between HPV+ and HPV- HNSCC cell lines. Among these proteins, we selected two candidates to validate our proteomic approach and studied their involvement in the carcinogenesis of HPV+ head and neck cancers. To this end, we performed immunohistochemistry on two clinical series (50 HPV+ oral SCC patients and 50 HPV- oral SCC patients) to support our results. In summary, this study aimed to establish a proteomic signature of HPV infection in head and neck cancer in order to better understand the mechanisms by which HPV drives head and neck carcinogenesis.

2. Materials and Methods

2.1. Cell Lines. The cell lines used in this study, which were derived from head and neck squamous cell carcinomas, are described in Table 1. Previous to the experiences described below, we performed PCR using E6 and E7 primers to confirm the HPV status of each cell line. The 93VU-147T cell line was obtained from Dr. de Winter (University Medical Center of Amsterdam). The UPCI-SCC-131, Detroit 562, UPCI-SCC-90, and UPCI-SCC-154 cell lines were grown in Minimum Essential Medium (MEM, Gibco Life Technologies, Paisley,

UK) supplemented with 10% fetal bovine serum (FBS, Lonza, Verviers, Belgium), 2% L-glutamine (PAA Laboratories, Pasching, Austria), 1% penicillin/streptomycin (PAA Laboratories, Pasching, Austria), and 1% nonessential amino acids (Gibco Life Technologies, Paisley, UK) at 37°C in a humidified 95% air-5% CO₂ atmosphere. The FaDU and 93VU-147T cell lines were grown in Dulbecco's Modified Eagle Medium (DMEM, Lonza, Verviers, Belgium) supplemented with 10% FBS, 2% L-glutamine, and 1% penicillin/streptomycin at 37°C in a humidified 95% air-5% CO₂ atmosphere. The culture medium was changed three times each week, and the cells were passaged when they reached 90% confluence. Table 1 presents the characteristics of the cell lines used in this study.

2.2. Protein Extraction and Sample Preparation. For total protein extraction, cells were washed twice in cold PBS and centrifuged, and the cell pellets were stored at -80°C. Protein extraction was performed using 6 M guanidinium chloride (lysis buffer from the ICPL kit, SERVA, Germany). The solution was then ultrasonicated for 3 × 10 sec (60% amplitude, U50 IKatechnik, IMLAB, Boutersem, Belgium) and incubated for 20 min at room temperature. The supernatant was recovered by centrifugation (13,000 rpm for 30 min at 4°C), and the protein concentration was determined according to the Bradford method, using bovine gamma-globulin as a standard.

The proteins were reduced, and their cysteines were alkylated using an ICPL kit (SERVA). The proteins were recovered via acetone precipitation and digested into peptides using trypsin at an enzyme/substrate ratio of 1:50 overnight at 37°C. The next day, trypsin digestion was stopped by adding 0.1% formic acid.

2.3. Proteomic Analysis: LC MS/MS Analysis. Protein identification and quantification were performed using a label-free strategy on an UHPLC-HRMS platform (Eksigent 2D Ultra and AB SCIEX TripleTOF 5600). The peptides (2 µg) were separated on a 25 cm C18 column (Acclaim PepMap100, 3 µm, Dionex) using a linear gradient (5–35% over 120 min) of acetonitrile (ACN) in water containing 0.1% formic acid at a flow rate of 300 nL min⁻¹. To obtain the highest possible retention time stability, which is required for label-free quantification, the column was equilibrated with a 10× volume of 5% ACN before each injection. Mass spectra (MS) were acquired across 400–1500 m/z in high-resolution mode with a 500 msec accumulation time. The precursor selection

parameters were as follows: intensity threshold 200 cps, 50 precursors maximum per cycle, 50 msec accumulation time, and 15 sec exclusion after one spectrum. These parameters led to a duty cycle of 3 sec per cycle, ensuring that high-quality extracted ion chromatograms (XICs) were obtained for peptide quantification.

2.4. Data Processing. ProteinPilot Software (v4.1) was used to conduct a database search against the UniProt Trembl database (09/30/2011 version), which was restricted to *Homo sapiens* entries. The search parameters included differential amino acid mass shifts for carbamidomethyl cysteine, all biological modifications, amino acid substitutions, and missed trypsin cleavage.

For peptide quantification, PeakView was used to construct XICs for the top 5 peptides of each protein identified with an FDR lower than 1%. Only unmodified and unshared peptides were used for quantification. Peptides were also excluded if their identification confidence was below 0.99, as determined by ProteinPilot. A retention time window of 2 min and a mass tolerance of 0.015 m/z were used. The calculated XICs were exported into MarkerView, and they were normalized based on the summed area of the entire run. Only proteins presenting a fold change higher/lower than 1.5/0.6 with a *P* value lower than 0.05 across the 3 biological replicates analyzed were taken into account for metabolic characterization. Fold changes were assessed using Student's *t*-test. Finally, proteins identified with 1 peptide were validated manually.

2.5. Immunofluorescence Staining. Cells were seeded at a density of 5×10^5 cells/well in 12-well plates containing sterile round glass coverslips and grown at 37°C and 5% CO₂ for 5 days. The cells were washed with PBS and fixed with 4% paraformaldehyde for 15 min. The fixed cells were rinsed with PBS, permeabilized with 0.1% Triton X-100 in PBS for 15 min and blocked with 0.05% casein for 20 min. Then, the cells were treated overnight with primary antibodies against PSCA (Pierce anti-PSCA rabbit polyclonal antibody, Thermo Scientific, Rockford, USA) and EEFl α (anti-EEFl α rabbit antibody (N-term), Abgent, Huisen, The Netherlands), which were diluted 1:50 in blocking solution. The next day, the cells were washed with PBS containing 0.1% Triton X-100 and incubated with Alexa Fluor 488-conjugated anti-rabbit IgG (Invitrogen, Gent, Belgium) for 1 h. The cells were washed with PBS containing 0.1% Triton X-100 for 15 min, rinsed with distilled water for 10 min and mounted with Vectashield Mounting Medium containing DAPI (Vector Laboratories). The cells were observed by confocal microscopy using an Olympus FV1000D laser scanning inverted microscope (Olympus, Hamburg, Germany). The exposure time of each photo was 27.59 s/frame, pictures were captured at 1600 pix/1600 pix, and the pixel time was 10.0 μ s/pix. The background noise was adjusted in the same manner and to the same level for each picture. Each picture was analyzed semi-quantitatively.

2.6. Western Blot Analysis. Proteins were extracted from cells using BugBuster Protein extraction reagent (Novagen,

Darmstadt, Germany), and the protein concentrations of the extracts were determined using a Bio-Rad protein assay (BioRad Laboratories, München, Germany). Four microliters 4 $\times$ LDS sample buffer (NuPAGE, Invitrogen) and 1 μ L 20 $\times$ reducing agent (Fermentas) were added to each protein extract, and the sample volume was brought to 20 μ L with deionized water. The samples were heated at 95°C for 5 min, and 30 μ g of proteins was separated on 4–20% Mini Protean Gels (BioRad Laboratories, München, Germany). After electrophoresis, the proteins were electrotransferred onto nitrocellulose membranes (Hybond ECL, Amersham). Nonspecific binding sites were blocked by incubation with PBS containing 5% nonfat milk at room temperature for 1 h. Immunodetection was performed overnight at 4°C using anti-EEFl α (anti-EEFl α rabbit antibody (N-term), Abgent, Huisen, The Netherlands) and anti-PSCA (Pierce anti-PSCA rabbit polyclonal antibody, Thermo Scientific, Rockford, USA) antibodies, which were diluted 1:100 in PBS containing 2% nonfat milk. The membrane was washed three times with PBS and incubated for 1 h at room temperature with HRP-conjugated goat anti-rabbit IgG (GE Healthcare Life Sciences, Buckinghamshire, UK), which was diluted in PBS containing 2% nonfat milk. The bound peroxidase was detected using the SuperSignal West Femto kit (Roche), and the bands were visualized by exposing the membranes to photosensitive film (Hyperfilm ECL, Amersham Pharmacia Biotech).

2.7. Patients and Tissue Samples. We examined 100 formalin-fixed, paraffin-embedded oral SCC specimens obtained from patients who underwent radical curative surgery between January 2004 and December 2008 at Saint Pieter's Hospital (Brussels) or the EpiCURA Center (Baudour). The tumors were classified according to the TNM classification of the International Union Against Cancer. Table 2 presents the clinical data of our patients. Among these 100 cases, 50 were HPV+ and 50 were HPV-. This study was approved by the Saint Pieter's Hospital Institutional Review Board (AK/09-09-47/3805AD).

2.8. HPV Detection and Typing. HPV detection and typing of paraffin-embedded tissues were performed as described in our previous work [9]. DNA extraction was performed using a QIAamp DNA Mini Kit (Qiagen, Benelux, Belgium), according to the manufacturer's protocol. HPV was detected using PCR with GP5+/GP6+ primers. All DNA extracts were analyzed for the presence of 18 different HPV genotypes using a TaqMan-based real-time quantitative PCR targeting type-specific sequences of the following viral genes: 6 E6, 11 E6, 16 E7, 18 E7, 31 E6, 33 E6, 35 E6, 39 E7, 45 E7, 51 E6, 52 E7, 53 E6, 56 E7, 58 E6, 59 E7, 66 E6, 67 L1, and 68 E7. In each PCR assay, β -globin levels were assessed using real-time quantitative PCR to verify the quality of the DNA in the samples and measure the amount of input DNA.

2.9. Immunohistochemistry of HPV+ and HPV- Oral Carcinoma Samples. All tumors samples were fixed for 24 h in 10% buffered formaldehyde, dehydrated, and embedded in paraffin. Immunohistochemistry was performed on 5 μ m thick

TABLE 2: Clinical data of the 100 oral SCC patients.

Variables	Number of cases
Age (years)	
Range	36–90
Mean	58
Sex	
Male	82
Female	18
Anatomic site	
Cheeks	4
Mouth floor	32
Tongue	36
Gums	8
Mandible	5
Palate	2
Retromolar trigone	2
Lips	2
Other	9
Grade (differentiation)	
Well	30
Moderately	51
Poorly	19
TNM stage	
T1-T2	72
T3-T4	28
N stage	
N0	53
N1	12
N2	33
N3	2
Metastasis	
M0	100
M1	0
Risk factors	
Tobacco (90 cases)	
Smoker	67
Nonsmoker	16
Former smoker	7
Alcohol (90 cases)	
Drinker	58
Nondrinker	9
Former drinker	23
Histology	
Bone infiltration	2
Perineural invasion	10
Positive node	19
Capsular evasion	11
Recurrence	
Local	11
Ganglionic	6
Distant metastases	4

sections mounted on silane-coated glass slides. The paraffin-embedded tissue specimens were deparaffinized in toluene, soaked in ethanol, and then soaked in PBS. They were pre-treated in a pressure cooker (11 min for PSCA and 6 min for EEFl α) in a 10% citrate buffer solution (for EEFl α) or a 10% EDTA solution (for PSCA) to unmask the antigens. Then, the sections were incubated in 0.06% hydrogen peroxide for 5 min to block endogenous peroxidase activity, rinsed in PBS, blocked with Protein Block (Serum-Free, Dako, Carpinteria, USA), and incubated at 4°C overnight with rabbit anti-PSCA (Thermo Scientific, Rockford, USA) or anti-EEFl α (BioConnect, TE Huissen, The Netherlands). The next day, the tissues were incubated with Post Blocking Antibody for 15 min, followed by PowerVision (ImmunoLogic, Duiven, The Netherlands) for 30 min. The slides were washed with PBS between incubation steps. Finally, the localization of the antibody/antigen complex was visualized by staining with DAB (BioGenex, Fremont, USA), and the sections were counterstained with Luxol Fast Blue and mounted with a synthetic medium. To exclude antigen-independent staining, controls, for which the incubation step with the primary antibody was omitted, were examined. In all cases, these controls were negative.

2.10. Semiquantitative Immunohistochemical Analysis. Two independent investigators, who were blinded to the clinical details of the patients, assessed PSCA and EEFl α immunoreactivities in all tumor areas using an optical microscope (Axiocam MRc5, Zeiss). The mean intensity (MI) was defined as follows: 0 (negative), 1 (weak), 2 (moderate), and 3 (strong). The percentage of immunopositive cells (labeling index, LI) was categorized as follows: 0 (0% positive cells), 1 (1–25%), 2 (26–75%), and 3 (76–100%). Statistical analysis was performed using the Mann-Whitney test to compare the MI and LI values between the HPV+ and HPV– samples.

3. Results

3.1. Protein Profiling of HPV+ versus HPV– Head and Neck Cancer Cell Lines. Protein profiling using label-free quantification was conducted to identify proteins whose expression was altered by HPV infection. To elucidate the specific effects of HPV in head and neck carcinogenesis and identify potential candidates, we compared the differential patterns of protein expression between one HPV– cell line (FaDU) and two HPV+ cell lines (93VU-147T and UPCI-SCC90). Proteins extracts were analyzed in triplicate for each cell line using tandem mass spectrometry.

For this analysis, we were interested in proteins that had increased or decreased expression levels and are clinically relevant.

Analysis of the three cancer cell lines identified 2221 proteins, among which 155 were differentially expressed between the HPV– and HPV+ cells with significant *P* values of <0.01; 56 of these were downregulated, and 99 were upregulated (Table 3). Two interesting candidates caught our attention due to their known properties and their large fold changes. The expression of prostate stem cell antigen (PSCA)

TABLE 3: Proteins with decreased and increased abundance between the HPV– cell line and the HPV+ cell lines.

Accession number	P value	Fold change	Protein name	Number of peptide identified (95%)
tr D3DWI6 D3DWI6_HUMAN	0.007	0.007	Prostate stem cell antigen	1
tr Q6LES2 Q6LES2_HUMAN	0.000005	0.045	ANXA4 protein	22
tr B3KY42 B3KY42_HUMAN	0.001	0.062	cDNA FLJ46788 fis, clone TRACH3028855, highly similar to Pseudouridylate synthase 7	1
tr B4E2Q6 B4E2Q6_HUMAN	0.003	0.093	Regulation of nuclear pre-mRNA domain-containing protein 2	2
tr F8WE04 F8WE04_HUMAN	0.00156	0.111	Heat shock protein beta-1	54
tr Q59GW6 Q59GW6_HUMAN	0.00375	0.134	Acetyl-CoA acetyltransferase, cytosolic variant	20
tr B7Z992 B7Z992_HUMAN	0.00369	0.137	cDNA FLJ53698, highly similar to Gelsolin	39
tr A8K287 A8K287_HUMAN	0.00793	0.143	Synaptosomal-associated protein	1
tr A8K5J7 A8K5J7_HUMAN	0.00757	0.150	cDNA FLJ77290, highly similar to Homo sapiens BCL2-associated athanogene 5	1
tr B2R4I8 B2R4I8_HUMAN	0.00098	0.159	cDNA, FLJ92106, highly similar to Homo sapiens adaptor-related protein complex 3, sigma 1 subunit(AP3S1),	2
tr E9PPU0 E9PPU0_HUMAN	0.00505	0.168	Epiplakin	97
tr B7Z6B8 B7Z6B8_HUMAN	0.00178	0.171	2,4-dienoyl-CoA reductase, mitochondrial	10
tr Q6NVI1 Q6NVI1_HUMAN	0.00008	0.197	MARCKS protein	26
tr C9JEJ2 C9JEJ2_HUMAN	0.00782	0.199	Choline-phosphate cytidyltransferase A	15
tr Q9BRV4 Q9BRV4_HUMAN	0.00187	0.202	Vesicle-associated membrane protein 3 (Cellubrevin)	3
tr B2RCZ7 B2RCZ7_HUMAN	0.00005	0.204	Ethylmalonic encephalopathy 1, isoform CRA_a	18
tr B4DL87 B4DL87_HUMAN	0.00444	0.206	cDNA FLJ52243, highly similar to Heat-shock protein beta-1	70
tr B7WPG3 B7WPG3_HUMAN	0.00444	0.208	Heterogeneous nuclear ribonucleoprotein L-like	1
tr Q6IAX6 Q6IAX6_HUMAN	0.00052	0.213	3'-phosphoadenosine 5'-phosphosulfate synthase 1 OS	1
tr E7EMB1 E7EMB1_HUMAN	0.00413	0.227	Switch-associated protein 70	9
tr E9PMV1 E9PMV1_HUMAN	0.00202	0.238	Plectin	10
tr F5GXF7 F5GXF7_HUMAN	0.00479	0.252	Zinc finger protein 185	16
tr E5RJR5 E5RJR5_HUMAN	0.00022	0.252	S-phase kinase-associated protein 1	4
tr E7ESP4 E7ESP4_HUMAN	0.00135	0.259	Integrin alpha-2	12
tr Q96IF9 Q96IF9_HUMAN	0.00454	0.273	VCP protein	112
tr F8W785 F8W785_HUMAN	0.00221	0.276	Golgi integral membrane protein 4	1
tr B7Z5V6 B7Z5V6_HUMAN	0.00881	0.278	cDNA FLJ57046, highly similar to Lysosomal alpha-glucosidase	4
tr A6NEL0 A6NEL0_HUMAN	0.00582	0.279	Non-histone chromosomal protein HMG-14	19
tr G0TQY6 G0TQY6_HUMAN	0.00471	0.281	Lutheran blood group	19
tr A8K4W6 A8K4W6_HUMAN	0.00045	0.287	Phosphoglycerate kinase	123
tr Q53RU4 Q53RU4_HUMAN	0.00154	0.292	Putative uncharacterized protein MSH2	4
tr A8K2Y9 A8K2Y9_HUMAN	0.0011	0.308	6-phosphogluconate dehydrogenase, decarboxylating	33
tr B3KMOV5 B3KMOV5_HUMAN	0.00078	0.319	cDNA FLJ12728 fis, clone NT2RP2000040, highly similar to Protein FAM62A	9
tr B3KMN7 B3KMN7_HUMAN	0.00131	0.320	cDNA FLJ11717 fis, clone HEMBA1005241	5
tr B4DN60 B4DN60_HUMAN	0.00015	0.323	Asparagine-tRNA ligase, cytoplasmic	10
tr B1ANK7 B1ANK7_HUMAN	0.00465	0.347	Fumarate hydratase	19

TABLE 3: Continued.

Accession number	P value	Fold change	Protein name	Number of peptide identified (95%)
tr Q0VDC6 Q0VDC6_HUMAN	0.00257	0.357	FKBP1A protein	9
tr C8KIL8 C8KIL8_HUMAN	0.00769	0.368	Glutathione reductase delta8 alternative splicing variant	1
tr B4DUK1 B4DUK1_HUMAN	0.00161	0.375	cDNA FLJ51310, moderately similar to Peroxiredoxin-6	10
tr E9PP14 E9PP14_HUMAN	0.00564	0.383	GDP-L-fucose synthase	1
tr D6RE99 D6RE99_HUMAN	0.00776	0.399	Histidine triad nucleotide-binding protein 1	8
tr B1AKP7 B1AKP7_HUMAN	0.00099	0.403	TAR DNA binding protein	11
tr Q6FHQ6 Q6FHQ6_HUMAN	0.00442	0.418	IDH1 protein	21
tr A8K4I2 A8K4I2_HUMAN	0.00771	0.421	Histone 1, H1c	123
tr A0PK02 A0PK02_HUMAN	0.00526	0.424	PLXNB2 protein	3
tr Q6IAW5 Q6IAW5_HUMAN	0.00939	0.446	CALU protein	22
tr Q6ZNW0 Q6ZNW0_HUMAN	0.0098	0.449	cDNA FLJ27036 fis, clone SLV08019, highly similar to Homo sapiens stomatin (EPB72)-like 2 (STOML2)	10
tr A4UCS8 A4UCS8_HUMAN	0.00267	0.455	Enolase	130
tr Q5TZZ9 Q5TZZ9_HUMAN	0.00184	0.461	ANXA1 protein	96
tr E2DRY6 E2DRY6_HUMAN	0.00118	0.504	Enolase	217
tr A4D105 A4D105_HUMAN	0.00122	0.514	Replication protein A3, 14 kDa	7
tr Q5TCI8 Q5TCI8_HUMAN	0.00168	0.530	Lamin A/C	119
tr B2R5W3 B2R5W3_HUMAN	0.00065	0.566	cDNA, FLJ92658, highly similar to Homo sapiens poly (ADP-ribose) polymerase family, member 1 (PARP1)	51
tr B4E0E1 B4E0E1_HUMAN	0.00065	0.566	cDNA FLJ53442, highly similar to Poly (ADP-ribose) polymerase 1	52
tr D6W5C0 D6W5C0_HUMAN	0.0096	0.608	Spectrin, beta, nonerythrocytic 1, isoform CRA_b	39
tr E9KL44 E9KL44_HUMAN	0.00912	0.646	Epididymis tissue sperm binding protein	39
tr B7Z6F8 B7Z6F8_HUMAN	0.00713	1.244	Clathrin interactor 1	6
tr A8K7A4 A8K7A4_HUMAN	0.00524	1.414	cDNA FLJ76904, highly similar to Homo sapiens methionine adenosyltransferase II, beta (MAT2B)	12
tr F8WDI0 F8WDI0_HUMAN	0.00874	1.505	Ubiquitin-like-conjugating enzyme ATG3	2
tr B3KRT1 B3KRT1_HUMAN	0.00437	1.706	Inositol-3-phosphate synthase 1	11
tr Q6PK50 Q6PK50_HUMAN	0.0069	1.788	HSP90AB1 protein	65
tr Q6NVC0 Q6NVC0_HUMAN	0.00315	1.80	SLC25A5 protein	37
tr E5RH41 E5RH41_HUMAN	0.00169	1.848	Transcription initiation factor IIE subunit beta	1
tr B4DYH1 B4DYH1_HUMAN	0.00023	1.878	Heat shock 105 kDa/110 kDa protein 1, isoform CRA_b	52
tr E9PQI8 E9PQI8_HUMAN	0.00195	1.888	U4/U6.U5 tri-snRNP-associated protein 1	3
tr B5BTY7 B5BTY7_HUMAN	0.00798	1.966	T-complex protein 1 subunit beta	46
tr B4DUG4 B4DUG4_HUMAN	0.00275	1.975	cDNA FLJ51308	1
tr B3KTJ9 B3KTJ9_HUMAN	0.00804	1.975	cDNA FLJ38393 fis, clone FEBRA2007212	15
tr D6R938 D6R938_HUMAN	0.00024	1.986	Calcium/calmodulin-dependent protein kinase (CaM kinase) II delta	2
tr A8K259 A8K259_HUMAN	0.00046	2.070	cDNA FLJ78501, highly similar to Homo sapiens serpin peptidase inhibitor, clade H (heat shock protein 47), member 1, (collagen binding protein 1) (SERPINH1)	18
tr Q54A51 Q54A51_HUMAN	0.00291	2.079	Basigin (Ok blood group), isoform CRA_a	20

TABLE 3: Continued.

Accession number	P value	Fold change	Protein name	Number of peptide identified (95%)
tr Q6IPH7 Q6IPH7_HUMAN	0.00287	2.131	RPL14 protein	19
tr A8K9U6 A8K9U6_HUMAN	0.00504	2.132	cDNA FLJ76121, highly similar to Homo sapiens zinc finger CCCH-type, antiviral 1 (ZC3HAV1)	7
tr D3DPU2 D3DPU2_HUMAN	0.00049	2.135	Adenylyl cyclase-associated protein	59
tr B3KN49 B3KN49_HUMAN	0.00667	2.165	cDNA FLJ13562 fis, clone PLACE1008080, highly similar to Homo sapiens hexamethylene bis-acetamide inducible 1 (HEXIM1)	6
tr E9PR70 E9PR70_HUMAN	0.0005	2.167	Serpin H1	17
tr Q05D43 Q05D43_HUMAN	0.00597	2.195	YBX1 protein	25
tr E7EQV9 E7EQV9_HUMAN	0.00711	2.247	Ribosomal protein L15	5
tr A8K2Q6 A8K2Q6_HUMAN	0.00501	2.278	Peptidyl-prolyl cis-trans isomerase	3
tr Q05CM9 Q05CM9_HUMAN	0.000005	2.287	PSIP1 protein	18
tr Q7L7Q6 Q7L7Q6_HUMAN	0.00109	2.321	RTN4	6
tr Q5U077 Q5U077_HUMAN	0.00247	2.379	L-lactate dehydrogenase	38
tr F5GZA8 F5GZA8_HUMAN	0.00582	2.384	SH3 domain-binding protein 1	6
tr E7EPK6 E7EPK6_HUMAN	0.00396	2.394	40S ribosomal protein S24	7
tr Q8TBR3 Q8TBR3_HUMAN	0.00685	2.414	Fusion (Involved in t(12;16) in malignant liposarcoma)	33
tr A8MX94 A8MX94_HUMAN	0.00964	2.475	Glutathione S-transferase P	50
tr B4DUI3 B4DUI3_HUMAN	0.00619	2.484	Eukaryotic translation initiation factor 3 subunit J	10
tr Q6PIN4 Q6PIN4_HUMAN	0.00019	2.492	IQGAP1 protein	64
tr A4QPB0 A4QPB0_HUMAN	0.00019	2.492	IQ motif containing GTPase activating protein 1	83
tr B7ZBH1 B7ZBH1_HUMAN	0.00876	2.499	Eukaryotic translation initiation factor 6	9
tr B4DZI8 B4DZI8_HUMAN	0.00931	2.525	Coatomer protein complex, subunit beta 2	8
tr B4DWA0 B4DWA0_HUMAN	0.00454	2.535	cDNA FLJ54188, moderately similar to High mobility group protein HMG-I/HMG-Y	8
tr B4DY28 B4DY28_HUMAN	0.0063	2.556	cDNA FLJ61189, highly similar to Cysteine and glycine-rich protein 1	2
tr B7Z921 B7Z921_HUMAN	0.00179	2.601	cDNA FLJ61669, highly similar to Transcription elongation regulator 1	5
tr Q8NF45 Q8NF45_HUMAN	0.00368	2.657	FLJ00353 protein	8
tr F8WEE0 F8WEE0_HUMAN	0.00313	2.672	Protein NDRG1	1
tr E9PIM9 E9PIM9_HUMAN	0.00026	2.676	Ribonuclease H1	24
tr B4E2D3 B4E2D3_HUMAN	0.00154	2.685	Nuclear pore complex protein Nup50	4
tr Q6FI03 Q6FI03_HUMAN	0.00472	2.715	G3BP protein	27
tr B7Z7L3 B7Z7L3_HUMAN	0.00077	2.752	NADH-cytochrome b5 reductase 3	10
tr B1AH89 B1AH89_HUMAN	0.00436	2.775	Tubulin tyrosine ligase-like family, member 12	14
tr Q6IBT3 Q6IBT3_HUMAN	0.00347	2.783	CCT7 protein	37
tr Q53HV2 Q53HV2_HUMAN	0.00347	2.783	Chaperonin containing TCP1, subunit 7 (Eta) variant	45
tr Q5W0H4 Q5W0H4_HUMAN	0.00403	2.793	Tumor protein, translationally controlled 1	13
tr B4DZX7 B4DZX7_HUMAN	0.00318	2.817	Thioredoxin domain containing, isoform CRA_b	1
tr B3KRA1 B3KRA1_HUMAN	0.00016	2.844	cDNA FLJ33914 fis, clone CTONG2016575, highly similar to SON PROTEIN	3
tr B7Z8R6 B7Z8R6_HUMAN	0.00049	2.846	cDNA FLJ51445, highly similar to AMBP protein	1
tr Q6IAX2 Q6IAX2_HUMAN	0.0057	2.852	RPL21 protein	13

TABLE 3: Continued.

Accession number	P value	Fold change	Protein name	Number of peptide identified (95%)
tr B2R4F3 B2R4F3_HUMAN	0.00842	2.868	cDNA, FLJ92068, highly similar to Homo sapiens Rho GDP dissociation inhibitor (GDI) beta (ARHGDIB)	3
tr D3DQ70 D3DQ70_HUMAN	0.00312	2.882	SERPINE1 mRNA binding protein 1, isoform CRA_d	15
tr E7ERF4 E7ERF4_HUMAN	0.00326	2.973	Adenylosuccinate lyase	10
tr B2RAU8 B2RAU8_HUMAN	0.00573	3.071	cDNA, FLJ95131, highly similar to Homo sapiens nucleolar and coiled-body phosphoprotein 1 (NOLC1)	11
tr B4DIT0 B4DIT0_HUMAN	0.00069	3.098	Anion exchange protein 2	2
tr B5MCA4 B5MCA4_HUMAN	0.00511	3.111	Epithelial cell adhesion molecule	4
tr Q6GMS8 Q6GMS8_HUMAN	0.00075	3.140	Syntaxin-16	2
tr B3KN82 B3KN82_HUMAN	0.00899	3.209	cDNA FLJ13913 fis, clone Y79AA1000231, highly similar to Nucleolar protein NOP5	12
tr B4E0L0 B4E0L0_HUMAN	0.00362	3.211	cDNA FLJ54030, highly similar to Polymerase delta-interacting protein 3	9
tr D3DSF7 D3DSF7_HUMAN	0.00302	3.236	SON DNA binding protein, isoform CRA.b	7
tr F8VVL1 F8VVL1_HUMAN	0.00199	3.278	Density-regulated protein	6
tr A8K787 A8K787_HUMAN	0.0069	3.285	cDNA FLJ75273, highly similar to Homo sapiens solute carrier family 25 (mitochondrial carrier; adenine nucleotide translocator), member 4	17
tr B4DSL9 B4DSL9_HUMAN	0.00403	3.297	cDNA FLJ58748, highly similar to U3 small nucleolar RNA-associated protein 6homolog	2
tr B3KWL6 B3KWL6_HUMAN	0.00036	3.382	Methionine aminopeptidase	7
tr B3KPR5 B3KPR5_HUMAN	0.00165	3.421	cDNA FLJ32094 fis, clone OCBBF2000986, highly similar to Homo sapiens elongation factor Tu GTP binding domain containing 1, transcript variant 1	1
tr Q14222 Q14222_HUMAN	0.00673	3.562	EEF1A protein	108
tr Q16577 Q16577_HUMAN	0.00673	3.562	Elongation factor 1-alpha	143
tr Q53H88 Q53H88_HUMAN	0.0034	3.579	Dynactin 2 variant	7
tr Q59GP5 Q59GP5_HUMAN	0.00198	3.601	Eukaryotic translation elongation factor 1 alpha 2 variant	45
tr Q68CS0 Q68CS0_HUMAN	0.00079	3.630	Ornithine aminotransferase, mitochondrial	7
tr F5GXR3 F5GXR3_HUMAN	0.00387	3.972	Parathymosin	1
tr F5H8L6 F5H8L6_HUMAN	0.00141	3.996	Dipeptidyl peptidase 3	17
tr Q6IPS9 Q6IPS9_HUMAN	0.00459	4.001	Elongation factor 1-alpha	311
tr F8W940 F8W940_HUMAN	0.00537	4.120	CUGBP Elav-like family member 1	3
tr B7ZLC9 B7ZLC9_HUMAN	0.00416	4.234	GEMIN5 protein	3
tr Q6FIG4 Q6FIG4_HUMAN	0.00017	4.372	RAB1B protein	19
tr F5H4R6 F5H4R6_HUMAN	0.00067	4.373	Nucleosome assembly protein 1-like 1	32
tr Q6PK82 Q6PK82_HUMAN	0.00008	4.425	AP3D1 protein	5
tr B3KW52 B3KW52_HUMAN	0.0073	4.443	cDNA FLJ42145 fis, clone TESTI4000228, highly similar to Mus musculus ubiquitin family domain containing 1 (Ubf1), mRNA	2
tr E9PS95 E9PS95_HUMAN	0.00885	4.636	Mitochondrial glutamate carrier 1	1
tr Q6FH57 Q6FH57_HUMAN	0.00045	4.653	Peptidyl-prolyl cis-trans isomerase	4
tr B3KN79 B3KN79_HUMAN	0.00107	4.681	cDNA FLJ13894 fis, clone THYRO1001671, highly similar to 59 kDa 2'-5'-oligoadenylate synthetase-like protein	3

TABLE 3: Continued.

Accession number	P value	Fold change	Protein name	Number of peptide identified (95%)
tr Q53GW1 Q53GW1_HUMAN	0.00487	4.697	Vesicle transport-related protein isoform a variant (Fragment)	3
tr Q5U0I6 Q5U0I6_HUMAN	0.00098	4.810	RAB1A protein	14
tr Q5TBU5 Q5TBU5_HUMAN	0.00439	5.144	Adipose specific 2	1
tr E9PK25 E9PK25_HUMAN	0.000007	6.239	Cofilin-1	96
tr F8W7I9 F8W7I9_HUMAN	0.00003	6.928	Ran GTPase-activating protein 1	15
tr B3KU10 B3KU10_HUMAN	0.00049	7.509	Interferon-induced GTP-binding protein Mx1	22
tr Q75MY7 Q75MY7_HUMAN	0.0005	7.948	MX2	11
tr D2KFR9 D2KFR9_HUMAN	0.00057	8.090	Signal transducer and activator of transcription 1-alpha/beta	3
tr E9PCQ3 E9PCQ3_HUMAN	0.00031	8.511	Ubiquitin carboxyl-terminal hydrolase	1
tr B4DTE6 B4DTE6_HUMAN	0.0066	8.644	cDNA FLJ56243, highly similar to Melanoma-associated antigen 4	6
tr Q8IV97 Q8IV97_HUMAN	0.00356	10.882	Solute carrier family 7 (Cationic amino acid transporter, y+ system), member 5	3
tr Q96J85 Q96J85_HUMAN	0.00055	14.133	C-Mpl binding protein	1
tr F5H667 F5H667_HUMAN	0.00003	16.263	Aspartyl/asparaginyl beta-hydroxylase	4
tr A5GZA6 A5GZA6_HUMAN	0.000002	53.611	Cysteine-rich with EGF-like domain protein 2	2
tr B4DZM8 B4DZM8_HUMAN	0.00002	145.941	26S proteasome non-ATPase regulatory subunit 5	2

(Accession number: D3DWI6) was reduced 140-fold in the FaDu cells compared to the HPV+ cell lines. Moreover, PSCA has been reported to be oncogenic in some epithelial cells and a tumor suppressor in others. Eukaryotic elongation factor 1 α (EEF1 α) (Accession number: Q6IPS9) expression was four fold higher in the HPV- cells than the HPV+ cell lines. Its upregulation was recently reported to be associated with increased cell proliferation and oncogenic transformation.

3.2. PSCA and EEF1 α Expression in Different HPV+ and HPV- Head and Neck Cancer Cell Lines. To confirm our mass spectrometry results, we studied the expression of PSCA and EEF1 α by immunocytochemistry in six head and neck cancer cell lines: 3 HPV+ cell lines (93VU-147T, UPCI-SCC90 and UPCI-SCC154) and 3 HPV- cell lines (FaDu, Detroit and UPCI-SCC131). The results of the immunofluorescence analysis of PSCA in all cell lines are presented in Figure 1. PSCA was mainly nuclear, but it was also distributed at a low level throughout the cytoplasm. PSCA was overexpressed in HPV+ cell lines compared to HPV- cell lines (Figures 1(a), 1(b), and 1(c)). These results are consistent with those obtained in our proteomic analysis.

Figure 2 illustrates the differential expression of EEF1 α between HPV+ and HPV- cell lines. EEF1 α was primarily nuclear, but it was also diffuse throughout the cytoplasm. We also noted a marked difference in the expression of this protein in both cell populations (HPV+ and HPV-). In fact, as expected, confocal microscopy examination of EEF1 α revealed an increase in the intensity of the immunofluorescence signal in the HPV- cells (Figures 2(d), 2(e), and 2(f)) compared to the HPV+ cells, which showed weak expression of

EEF1 α (Figures 2(a), 2(b), and 2(c)). This observation was validated using western blotting to compare the EEF1 α expression levels of the cell lines used in our proteomic analysis. In FaDu cell extracts, a band was detected at 50 kDa, which corresponds to the mass of the EEF1 α protein (Figure 3). This band was not observed in the HPV+ cell lines. We used actin as a loading control, which was detected at 43 kDa in the extracts from all three cell lines (Figure 3). After several attempts, we were not able to validate PSCA expression by western blotting because the primary antibody was not suitable for this technique.

3.3. PSCA Protein Expression in Surgical Specimens of OSCC. Among the 50 HPV+ cases, qRT-PCR targeting 18 HPV subtypes revealed that 100% of the cases were infected by HPV-16, with two coinfections, HPV-53 and HPV-39. After confirming our results *in vitro*, we evaluated PSCA expression in clinical series of oral cancer. Fifty HPV+ and fifty HPV- oral cancer specimens were examined by immunohistochemistry. As shown in Figure 4(d), PSCA immunostaining was strong in both the cytoplasm and nucleus (Figure 4(d)). To determine whether there was differential protein expression, we compared the two groups (HPV+ versus HPV-) using a non-parametric Mann-Whitney test (Figure 4(e)). PSCA was significantly upregulated in the HPV+ oral tumors compared to the HPV- oral tumors ($P = 0.006$) in terms of the labeling index (LI), which corresponds to the percentage of immunopositive cells.

3.4. EEF1 α Protein Expression in Surgical Specimens of OSCC. Figures 5(c) and 5(d) present the results of our immunohistochemical analysis of EEF1 α expression in the same

FIGURE 1: Immunofluorescence staining of PSCA in three HPV+ cell lines ((a), (b), and (c)) and three HPV- cell lines with control DAPI staining ((d), (e), and (f)). Alexa Fluor 488 labeling; confocal microscopy; exposure time of 27.59 s/frame; capture condition of 1600 pix/1600 pix and pixel time of 10.0 μ s/pix.

clinical series (50 HPV+ OSCCs *versus* 50 HPV- OSCCs). EEFl α was localized in both the nucleus and cytoplasm, but significantly stronger staining intensity was observed in the nucleus (Figure 5(d)). As expected, semiquantitative analysis demonstrated that EEFl α expression was increased in HPV- carcinomas compared to HPV+ carcinomas. Indeed, a statistically significant difference in terms of the mean intensity (MI) values between the HPV+ and HPV- tumors

was calculated using a nonparametric Mann-Whitney test ($P = 0.03$) (Figure 5(e)).

4. Discussion

Recent advances have been made in our understanding of the relationship between head and neck carcinogenesis and HPV. Strong evidence indicates that HPV+ HNSCC

FIGURE 2: Immunofluorescence staining of EEFlα in three HPV+ cell lines with control DAPI staining ((a), (b), and (c)) and three HPV- cell lines ((d), (e), and (f)). Alexa Fluor 488 labeling; confocal microscopy; exposure time of 27.59 s/frame; capture condition of 1600 pix/1600 pix and pixel time of 10.0 μs/pix.

comprise a subclass of tumors with a different biology and different clinical properties and that affects specific demographic populations. HPV+ tumors occur in a younger age group, originate more frequently in the oropharynx, and have a lower T stage compared to HPV- tumors [15]. At the histopathological level, we distinguished distinct features of HPV+ tumors, including their identification as nonkeratinizing basal cells and their prominent “koilocytic” morphology

[16]. Concerning overall survival, the majority of studies agree that HPV-infected patients have a better prognosis. HPV+ and HPV- tumors also exhibit differences in tumor biology, with HPV+ tumors having fewer p53 mutations and displaying reduced association with tobacco and alcohol consumption [17, 18]. These observations suggest that HPV+ HNSCC and HPV- HNSCC should be considered two distinct cancers with distinct biological pathways: one driven

FIGURE 3: Western blot analysis demonstrating the upregulation of EEFl α in the HPV- cell line, FaDu.

by environmental agents (tobacco and alcohol) and the other driven by infectious agents (high-risk HPV subtypes). However, these two pathologic agents may interact and act synergistically to promote the development of HNSCC.

Despite the progress made in the field of HPV-related HNSCC, a paucity of literature exists with respect to studies investigating the biology of HPV infection in head and neck carcinogenesis. Disease predictors are important from both the clinical and molecular perspectives. Current HNSCC treatments are frequently associated with adverse side effects, and 50% of HNSCC patients die within two years of their initial diagnosis because two-thirds of patients have advanced cancer (stage III or IV) at diagnosis [19, 20]. Therefore, novel approaches are needed to aid clinicians by providing them relevant predictive candidates for the disease to improve patient management. Beyond the clinical challenges, understanding the molecular mechanisms underlying this disease is crucial for developing targeted therapies and individualizing treatment based on the biology of the tumor. In this context, we investigated the global protein expression of three head and neck cancer cell lines, two HPV+ and one HPV-. First, we compared the two populations to identify differences in their proteomic patterns and, consequently, potential candidates of HPV infection. Second, we validated the selected proteins using a clinical series of 100 oral SCC samples (50 HPV+ and 50 HPV-).

Over the past decade, technological advances have been made in the field of proteomics, leading to the identification of specific proteins that are differentially expressed in tumor and control specimens. Mass spectrometry is undoubtedly the most powerful technology for proteomics. The most current mass spectrometers present high resolving power and mass accuracy, allowing for the detection and quantification of thousands of proteins. Thus, clinical proteomics is a powerful diagnostic and prognostic technology. However, advances

in the proteomics field have resulted in publications describing numerous potential cancer markers that must be clinically validated prior to the development of a diagnostic test.

In our study, we used liquid chromatography coupled to electrospray ionization tandem mass spectrometry to analyze tryptic peptides from three cell lines (2 HPV+ and 1 HPV-). This technology allowed us to identify and quantify 2221 proteins, among which 155 were differentially expressed between the HPV- and HPV+ cells with significant *P* values of <0.01. The strength of our study lies in the clinical validation of our potential candidates. Indeed, there is a limitation in using cultured cells rather than clinical specimens, as the proteomes of cells grown *in vitro* may not accurately reflect those of *in vivo* cancer cells. However, if the selected protein candidates are further investigated by immunohistochemistry (IHC) using patient tissue samples, the proteomic analysis of cultured cells is entirely valid for the identification of putative candidates. Ye et al. identified 40 differentially expressed proteins between three paired oral SCC cell lines with different metastatic potentials. They were able to confirm their results by IHC and, consequently, identified superoxide dismutase 2 (SOD2) as a predictive marker for the diagnosis of metastasis [21].

Similarly, we validated several of the differentially expressed proteins between the HPV- and HPV+ populations in our study using three different methods. Immunocytochemistry and western blotting confirmed our mass spectrometry results, and IHC also demonstrated those statistically significant differences in 50 HPV+ and 50 HPV- oral SCC specimens. In fact, HPV+ oral carcinoma s overexpressed prostate stem cell antigen (PSCA) compared to HPV- oral carcinomas. PSCA was discovered fifteen years ago. It is a glycosylphosphatidylinositol (GPI)-anchored cell surface protein belonging to the Thy-1/Ly-6 family [22]. PSCA was initially identified in prostate cancer but is also expressed in epithelial cells of various organs, such as the bladder, kidney, skin, esophagus, stomach, placenta, and lung [23–26]. Little is known about its physiological functions and signaling cascade, but recently, it was defined as a “Jekyll and Hyde” molecule due to its expression pattern. PSCA seems to act as an oncogene in some cancers, such as prostate, bladder, renal and ovarian carcinomas, and as a tumor suppressor in others, including esophageal and gastric cancer [27]. To date, only one study reported decreased PSCA expression (100-fold) in HNSCC [25].

PSCA seems to be involved in cell growth regulation and to play some roles in signal transduction. Other members of the Ly-6 superfamily are involved in cell adhesion, cell migration, and the regulation of T lymphocyte regulation [28–30]. PSCA overexpression in prostate cancer is related to c-myc amplification [24]. In addition, siRNA-mediated knockdown of PSCA significantly reduces lung cancer cell growth [26]. The same observation was recently made in human prostate cancer cells [31]. Moreover, PSCA is downregulated in gallbladder, esophagus, and stomach tumors [23, 32], as well as our HPV- HNC cell line (FaDu). Therefore, it would be interesting to further validate and explore the clinical implications of PSCA.

FIGURE 4: Typical immunohistochemical staining profile of PSCA in HPV- (c) and HPV+ (d) oral tumors. The graph represents the results of the Mann-Whitney test of the PSCA mean labeling index values in the 50 HPV+ and 50 HPV- tumors (e). Panels (a) and (b) show positive and negative controls for PSCA in oral tumors, respectively.

Our second candidate protein, EEF1 α , was overexpressed in the HPV- cell line. EEF1 α is a GTP-binding protein that interacts with aminoacyl-tRNA to recruit and deliver it to the A site of the ribosome during the elongation phase of protein translation. In addition to its role in protein translation, EEF1 α is involved in cell migration, cell morphology, protein synthesis, actin cytoskeleton organization, and the modulation of apoptosis sensitivity [33, 34]. Due to its overexpression in many cancers, such as ovarian, breast, lung, and liver cancer, EEF1 α has been defined as a putative oncogene [35]. This protein is of particular interest because a previous study reported that its downregulation in prostate cancer cells

inhibits cell proliferation, invasion, and migration [36]. In contrast, increased EEF1 α expression is associated with increased cell proliferation, oncogenic transformation, and delayed cell senescence [37–39]. EEF1 also interacts with Akt to modulate its activity and regulate proliferation, survival, and motility in breast cancer cells [40]. Several authors reported that increased expression of this elongation factor is associated with tumorigenesis by enhancing the translation of genes promoting cell growth [38, 41].

To date, no clinical studies have demonstrated the involvement of PSCA or EEF1 α in head and neck carcinogenesis caused by viral infection, and their functions remain

FIGURE 5: Typical immunohistochemical staining profile of EEFl α in HPV- (c) and HPV+ (d) oral tumors. The graph represents the results of the Mann-Whitney test of the EEFl α mean labeling index values in the 50 HPV+ and 50 HPV- tumors (e). (a) and (b) show positive and negative controls for EEFl α in oral tumors, respectively.

to be elucidated. This study will aid in our understanding of the mechanisms used by HPV to promote the development of head and neck cancers. In conclusion, PSCA and EEFl1 meet several criteria, suggesting that they are involved in the biology of HPV-related HNSCC; however, further studies should be conducted to confirm our observations in a larger clinical series. Moreover, it will be interesting to perform functional experiments to understand the signaling pathways disrupted by HPV infection. By silencing several proteins, we plan to study the impact of gene extinction on cell proliferation, migration, invasion, and apoptosis to better understand the mechanisms used by HPV to drive carcinogenesis.

Conflict of Interests

The authors declare that there is no conflict of interests regarding the publication of this paper.

Acknowledgments

This work was partially financed by the FNRS under Grant “grand equipment” (no. 2877824). Géraldine Descamps is Ph.D. student who is supported by a Grant from the FNRS (Bourse Télévie).

References

- [1] O. Filleul, J. Preillon, E. Crompot, J. Lechien, and S. Saussez, "Incidence of head and neck cancers in Belgium: comparison with worldwide and French data," *Bulletin du Cancer*, vol. 98, no. 10, pp. 1173–1183, 2011.
- [2] A. A. Ankola, R. V. Smith, R. D. Burk, M. B. Prystowsky, C. Sarta, and N. F. Schlecht, "Comorbidity, human papillomavirus infection and head and neck cancer survival in an ethnically diverse population," *Oral Oncology*, vol. 49, no. 9, pp. 911–917, 2013.
- [3] C. C. R. Ragin and E. Taioli, "Survival of squamous cell carcinoma of the head and neck in relation to human papillomavirus infection: review and meta-analysis," *International Journal of Cancer*, vol. 121, no. 8, pp. 1813–1820, 2007.
- [4] A. Duray, G. Descamps, C. Decaestecker et al., "Human papillomavirus DNA strongly correlates with a poorer prognosis in oral cavity carcinoma," *Laryngoscope*, vol. 122, no. 7, pp. 1558–1565, 2012.
- [5] B. G. Hansson, K. Rosenquist, A. Antonsson et al., "Strong association between infection with human papillomavirus and oral and oropharyngeal squamous cell carcinoma: a population-based case-control study in southern Sweden," *Acta Oto-Laryngologica*, vol. 125, no. 12, pp. 1337–1344, 2005.
- [6] K. Rosenquist, J. Wennerberg, K. Annertz et al., "Recurrence in patients with oral and oropharyngeal squamous cell carcinoma: human papillomavirus and other risk factors," *Acta Oto-Laryngologica*, vol. 127, no. 9, pp. 980–987, 2007.
- [7] K. Morshed, "Association between human papillomavirus infection and laryngeal squamous cell carcinoma," *Journal of Medical Virology*, vol. 82, no. 6, pp. 1017–1023, 2010.
- [8] P. Ernoux-Neufcoeur, M. Arafa, C. Decaestecker et al., "Combined analysis of HPV DNA, p16, p21 and p53 to predict prognosis in patients with stage IV hypopharyngeal carcinoma," *Journal of Cancer Research and Clinical Oncology*, vol. 137, no. 1, pp. 173–181, 2011.
- [9] A. Duray, G. Descamps, M. Arafa et al., "High incidence of high-risk HPV in benign and malignant lesions of the larynx," *International Journal of Oncology*, vol. 39, no. 1, pp. 51–59, 2011.
- [10] M. L. Gillison, W. M. Koch, R. B. Capone et al., "Evidence for a causal association between human papillomavirus and a subset of head and neck cancers," *Journal of the National Cancer Institute*, vol. 92, no. 9, pp. 709–720, 2000.
- [11] H. C. Hafkamp, J. J. Manni, A. Haesevoets et al., "Marked differences in survival rate between smokers and nonsmokers with HPV 16-associated tonsillar carcinomas," *International Journal of Cancer*, vol. 122, no. 12, pp. 2656–2664, 2008.
- [12] W. Y. Lo, C. C. Lai, C. H. Hua et al., "S100A8 is identified as a biomarker of HPV18-infected oral squamous cell carcinomas by suppression subtraction hybridization, clinical proteomics analysis, and immunohistochemistry staining," *Journal of Proteome Research*, vol. 6, no. 6, pp. 2143–2151, 2007.
- [13] H. W. Ott, H. Lindner, B. Sarg et al., "Calgranulins in cystic fluid and serum from patients with ovarian carcinomas," *Cancer Research*, vol. 63, no. 21, pp. 7507–7514, 2003.
- [14] C. Melle, G. Ernst, R. Winkler et al., "Proteomic analysis of human papillomavirus-related oral squamous cell carcinoma: identification of thioredoxin and epidermal-fatty acid binding protein as upregulated protein markers in microdissected tumor tissue," *Proteomics*, vol. 9, no. 8, pp. 2193–2201, 2009.
- [15] S. Marur and A. A. Forastiere, "Head and neck cancer: changing epidemiology, diagnosis, and treatment," *Mayo Clinic Proceedings*, vol. 83, no. 4, pp. 489–501, 2008.
- [16] W. M. Koch, "Clinical features of HPV-related head and neck squamous cell carcinoma: presentation and work-up," *Otolaryngologic Clinics of North America*, vol. 45, no. 4, pp. 779–793, 2012.
- [17] W. H. Westra, J. M. Taube, M. L. Poeta, S. Begum, D. Sidransky, and W. M. Koch, "Inverse relationship between human papillomavirus-16 infection and disruptive p53 gene mutations in squamous cell carcinoma of the head and neck," *Clinical Cancer Research*, vol. 15, no. 2, pp. 366–369, 2008.
- [18] C. H. Chung and M. L. Gillison, "Human papillomavirus in head and neck cancer: its role in pathogenesis and clinical implications," *Clinical Cancer Research*, vol. 15, no. 22, pp. 6758–6762, 2009.
- [19] J. Bernier, C. Dommene, M. Ozsahin et al., "Postoperative irradiation with or without concomitant chemotherapy for locally advanced head and neck cancer," *The New England Journal of Medicine*, vol. 350, no. 19, pp. 1945–1952, 2004.
- [20] K. Lang, J. Menzin, C. C. Earle, J. Jacobson, and M. A. Hsu, "The economic cost of squamous cell cancer of the head and neck: findings from linked SEER-medicare data," *Archives of Otolaryngology, Head & Neck Surgery*, vol. 130, no. 11, pp. 1269–1275, 2004.
- [21] H. Ye, A. Wang, B. S. Lee et al., "Proteomic based identification of manganese superoxide dismutase 2 (SOD2) as a metastasis marker for oral squamous cell carcinoma," *Cancer Genomics and Proteomics*, vol. 5, no. 2, pp. 85–94, 2008.
- [22] R. E. Reiter, Z. Gu, T. Watabe et al., "Prostate stem cell antigen: a cell surface marker overexpressed in prostate cancer," *Proceedings of the National Academy of Sciences of the United States of America*, vol. 95, no. 4, pp. 1735–1740, 1998.
- [23] G. Bahrenberg, A. Brauers, H. G. Joost, and G. Jakse, "Reduced expression of PSCA, a member of the LY-6 family of cell surface antigens, in bladder, esophagus, and stomach tumors," *Biochemical and Biophysical Research Communications*, vol. 275, no. 3, pp. 783–788, 2000.
- [24] Z. Gu, G. Thomas, J. Yamashiro et al., "Prostate stem cell antigen (PSCA) expression increases with high gleason score, advanced stage and bone metastasis in prostate cancer," *Oncogene*, vol. 19, no. 10, pp. 1288–1296, 2000.
- [25] A. G. de Nooij-van Dalen, G. A. van Dongen, S. J. Smeets et al., "Characterization of the human Ly-6 antigens, the newly annotated member Ly-6K included, as molecular markers for head-and-neck squamous cell carcinoma," *International Journal of Cancer*, vol. 103, no. 6, pp. 768–774, 2003.
- [26] T. Kawaguchi, M. Sho, T. Tojo et al., "Clinical significance of prostate stem cell antigen expression in non-small cell lung cancer," *Japanese Journal of Clinical Oncology*, vol. 40, no. 4, pp. 319–326, 2010.
- [27] N. Saeki, J. Gu, T. Yoshida, and X. Wu, "Prostate stem cell antigen: a Jekyll and Hyde molecule?" *Clinical Cancer Research*, vol. 16, no. 14, pp. 3533–3538, 2010.
- [28] D. F. Stroncek, L. Caruccio, and M. Bettinotti, "CD177: a member of the Ly-6 gene superfamily involved with neutrophil proliferation and polycythemia vera," *Journal of Translational Medicine*, vol. 2, no. 1, article 8, 2004.
- [29] A. Hänninen, I. Jaakkola, M. Salmi, O. Simell, and S. Jalkanen, "Ly-6C regulates endothelial adhesion and homing of CD8⁺ T cells by activating integrin-dependent adhesion pathways,"

Proceedings of the National Academy of Sciences of the United States of America, vol. 94, no. 13, pp. 6898–6903, 1997.

- [30] S. K. Lee, B. Su, S. E. Maher, and A. L. M. Bothwell, "Ly-6A is required for T cell receptor expression and protein tyrosine kinase fyn activity," *The EMBO Journal*, vol. 13, no. 9, pp. 2167–2176, 1994.
- [31] Z. Zhao, W. Ma, G. Zeng, D. Qi, L. Ou, and Y. Liang, "Small interference RNA-mediated silencing of prostate stem cell antigen attenuates growth, reduces migration and invasion of human prostate cancer PC-3M cells," *Urologic Oncology*, vol. 31, no. 3, pp. 343–351, 2013.
- [32] H. Ono, N. Hiraoka, Y. S. Lee et al., "Prostate stem cell antigen, a presumable organ-dependent tumor suppressor gene, is down-regulated in gallbladder carcinogenesis," *Genes Chromosomes and Cancer*, vol. 51, no. 1, pp. 30–41, 2012.
- [33] S. R. Gross and T. G. Kinzy, "Translation elongation factor 1A is essential for regulation of the actin cytoskeleton and cell morphology," *Nature Structural and Molecular Biology*, vol. 12, no. 9, pp. 772–778, 2005.
- [34] A. Duttaroy, D. Bourbeau, X. L. Wang, and E. Wang, "Apoptosis rate can be accelerated or decelerated by overexpression or reduction of the level of elongation factor-1 α ," *Experimental Cell Research*, vol. 238, no. 1, pp. 168–176, 1998.
- [35] G. van Goietsenoven, J. Hutton, J. P. Becker et al., "Targeting of eEF1A with Amaryllidaceae isocarboxtyrils as a strategy to combat melanomas," *The FASEB Journal*, vol. 24, no. 11, pp. 4575–4584, 2010.
- [36] G. Zhu, W. Yan, H. C. He et al., "Inhibition of proliferation, invasion, and migration of prostate cancer cells by downregulating elongation factor-1 α expression," *Molecular Medicine*, vol. 15, no. 11-12, pp. 363–370, 2009.
- [37] B. T. Edmonds, J. Wyckoff, Y.-G. Yeung et al., "Elongation factor-1 α is an overexpressed actin binding protein in metastatic rat mammary adenocarcinoma," *Journal of Cell Science*, vol. 109, no. 11, pp. 2705–2714, 1996.
- [38] N. Anand, S. Murthy, G. Amann et al., "Protein elongation factor EEF1A2 is a putative oncogene in ovarian cancer," *Nature Genetics*, vol. 31, no. 3, pp. 301–305, 2002.
- [39] B. T. Edmonds, J. Murray, and J. Condeelis, "pH regulation of the F-actin binding properties of Dictyostelium elongation factor 1 α ," *The Journal of Biological Chemistry*, vol. 270, no. 25, pp. 15222–15230, 1995.
- [40] L. Pecorari, O. Marin, C. Silvestri et al., "Elongation factor 1 alpha interacts with phospho-Akt in breast cancer cells and regulates their proliferation, survival and motility," *Molecular Cancer*, vol. 8, no. 1, article 58, 2009.
- [41] N. Sonenberg, "Translation factors as effectors of cell growth and tumorigenesis," *Current Opinion in Cell Biology*, vol. 5, no. 6, pp. 955–960, 1993.